Virtual RA Forum®: Applying Recent Advances to Improve Quality Care

1.50 CME
90 MINS
$0 FEE
SAVE
Purple abstract OG image size

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by an educational grant from Pfizer, Inc.


Target Audience

The intended audience for this activity is rheumatologists and other health care professionals involved in the treatment of patients with RA.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Examine the underlying immunopathology of RA and resulting implications for biomarker testing and treatment.
  • Select treatment for patients with RA based on the latest clinical evidence and patient characteristics.
  • Assess the benefits and limitations of biosimilars for management of RA.
  • Implement best practices for the prevention of complications for patients with RA, including risk profiling and vaccination.

Faculty

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Professor of Medicine, Healthcare Policy and Research
Weill Medical College of Cornell University
Attending Rheumatologist
Hospital for Special Surgery
New York, NY

William F. C. Rigby, MD
Professor of Medicine, Microbiology, and Immunology
Dartmouth Geisel School of Medicine
Hanover, NH

Kevin Winthrop, MD, MPH
Professor of Infectious Diseases and Ophthalmology
Professor of Public Health and Preventive Medicine
Division of Infectious Diseases
Oregon Health & Science University
Portland, OR


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, January 28, 2019 to January 27, 2020.


How to Participate in this Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.


Faculty members report the following relationship(s)

Leonard H. Calabrese, DO
Consulting Fee: Amgen, GlaxoSmithKline, Horizon, Janssen, Pfizer, Regeneron, Sanofi, UCB
Speakers Bureau: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Janssen, UCB

Allan Gibofsky, MD, JD, MACR, FACP, FCLM
Consulting Fee: AbbVie, Celgene, Fluxion, Lilly, Novartis, Pfizer
Speakers Bureau: AbbVie, Celgene, Fluxion, Lilly, Novartis, Pfizer
Ownership Interest: AbbVie, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, Regeneron

William F. C. Rigby, MD
Consulting Fee: Bristol-Myers Squibb, Pfizer, Roche

Kevin Winthrop, MD, MPH
Consulting Fee: AbbVie, Bristol-Myers Squibb, Galapagos, Gilead, Lilly, Pfizer, UCB
Contracted Research: Bristol-Myers Squibb, UCB


Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.


Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com